

COMPANY FACT SHEET

Headquarters

Magnus Medical, Inc.
1350 Old Bayshore Highway, Suite 600
Burlingame, CA 94010

Employees

Over 30 employees

Financing

\$25M in Series A financing co-led by Jazz Venture Partners and Red Tree Venture Capital.

Magnus

A privately held medical device company that has developed the SAINT™ Neuromodulation System, a novel, rapid-acting treatment for treatment-resistant depression.

Granted Breakthrough Device Designation and 510(k) clearance by the U.S. Food & Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement from prior antidepressant medications in the current episode, the SAINT Neuromodulation System yields a new form of individualized neurostimulation for adults with treatment-resistant depression.

Magnus' leadership team includes Brett Wingeier, Ph.D., chief executive officer and Brandon Bentzley, M.D., Ph.D., chief scientific officer.

Technology and Clinical Results

The SAINT Neuromodulation System is a novel innovation that is significantly impacting the treatment of severe depression. SAINT uses structural and functional MRI scans to inform a proprietary algorithm that identifies the optimal anatomic target for focused neurostimulation in people with MDD. SAINT was developed at Stanford and licensed exclusively to Magnus in October 2021 for commercialization.

For the first time, advanced tools for processing MRI-based images of the brain are used to steer a specialized, high-dose pattern of magnetic pulses to induce neurons to fire. This stimulation modifies activity in brain networks related to depression, changing the brain's circuitry to more effectively treat MDD.

Results from clinical trials show that SAINT is safe and well-tolerated.

- In a double-blinded randomized controlled trial (RCT) evaluating SAINT, 14 people received active treatment and another 15 people received sham (placebo) treatment. The results show that 79% of people in the active treatment arm entered remission following the five-day treatment protocol, compared to people in the sham arm, where only 13% entered remission.
- The SAINT Neuromodulation System has additionally been studied in non-RCT (open-label) studies. Overall, the therapy has been shown to be effective in the treatment of MDD, with approximately 80-90% of patients achieving remission of depression symptoms following the five-day treatment protocol.

Media Resources

Brett Wingeier, Ph.D., co-founder and CEO

Brandon Bentzley, M.D., Ph.D., co-founder and CSO

#

Media Contact:

Amy Cook

amy@magnusmed.com

+1 925.200.2125